Dr. Michael Cheng, DO

Dr. Cheng practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Cheng's NPI, 1003109513, was assigned on May 17, 2011. Dr. Cheng graduated from WesternU College of Osteopathic Medicine of the Pacific in 2011. Dr. Cheng's California license number on file is 20A12483.

Dr. Cheng's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Cheng's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cheng practices. Vendor and product names are available with a free account.

Rheumatology is Dr. Cheng's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Cheng is board certified in internal medicine by the American Board of Internal Medicine. Dr. Cheng has a license on file in California.

Dmand AI lists acute kidney failure, arteritis, arthritis, bursitis, carpal tunnel syndrome, chronic diabetes, chronic kidney disease and chronic lung disease among the conditions Dr. Cheng treats.

CMS data shows 2,851 Medicare services from Dr. Cheng across 10 procedure codes in 2024, for 255 Medicare patients. Medicare paid $82,929 for them.

CMS counts 255 Medicare patients who saw Dr. Cheng in 2024. The largest group is 65 to 74, with 127 patients. 75% of them have arthritis, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cheng's median patient age at 56, with 76% women.

In 2024, Dr. Cheng wrote 1,166 Medicare Part D claims for 166 patients. 76% of them were for generic drugs. CMS names the drug for 1,042 of them, across 36 drugs with 11 or more claims each, at $1,186,893 in total drug cost. In 2023, CMS named 1,064 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Cheng for performance year 2024, reported through an alternative payment model (APM). Dr. Cheng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cheng as offering telehealth.

Dmand AI links 5 papers to Dr. Cheng, published from 2020 to 2023. 2023 was the busiest year, with 2. Dr. Cheng has published most often in J Thorac Dis. Dr. Cheng's most frequent co-authors are Patrick B. Murphy, MD, Chay Bae, DO and Sheetal Ramesh Desai, MD.

CMS Open Payments shows 14 general payments to Dr. Cheng from 9 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. Pfizer Inc. paid the most, $3,700. It also lists 1 research payment totaling $940 in 2024.

Dr. Cheng graduated from WesternU College of Osteopathic Medicine of the Pacific in 2011.

Dr. Cheng is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.